Galmed Pharmaceuticals receives new patent for Aramchol treatment.

Galmed Pharmaceuticals received a new patent in South Korea for its lead compound, Aramchol, which is a first-in-class drug candidate for treating non-alcoholic steatohepatitis (NASH). The patent covers a combination therapy of Aramchol and Rezdiffra (MGL-3196) for NASH treatment. The patent, which expires in 2042, complements earlier patents granted by USPTO, Europe, Canada, and other jurisdictions.